Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
Roy S. Herbst, Yi‐Long Wu, Thomas John, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 10, pp. 1830-1840
Open Access | Times Cited: 229

Showing 1-25 of 229 citing articles:

Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC
Masahiro Tsuboi, Roy S. Herbst, Thomas John, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 2, pp. 137-147
Closed Access | Times Cited: 332
Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
Yi‐Long Wu, Rafał Dziadziuszko, Jin Seok Ahn, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 14, pp. 1265-1276
Closed Access | Times Cited: 133
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
Giannis Mountzios, Jordi Remón, Lizza E.L. Hendriks, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 10, pp. 664-677
Closed Access | Times Cited: 106
Lung cancer in patients who have never smoked — an emerging disease
Jaclyn LoPiccolo, Alexander Gusev, David C. Christiani, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 2, pp. 121-146
Open Access | Times Cited: 69
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer
Pasi A. Jänne, David Planchard, Kunihiko Kobayashi, et al.
Journal of Clinical Oncology (2023) Vol. 42, Iss. 7, pp. 808-820
Open Access | Times Cited: 54
Oncogenic alterations in advanced NSCLC: a molecular super-highway
Alex Friedlaender, M. Pérol, Giuseppe Luigi Banna, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 36
Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer
Jonathan Spicer, Tina Cascone, Murry W. Wynes, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 10, pp. 1373-1414
Open Access | Times Cited: 25
Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidance
Raffaella Casolino, Philip Beer, Debyani Chakravarty, et al.
CA A Cancer Journal for Clinicians (2024) Vol. 74, Iss. 3, pp. 264-285
Open Access | Times Cited: 21
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study
Amin H. Nassar, So Yeon Kim, Jacqueline V. Aredo, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 6, pp. 928-940
Closed Access | Times Cited: 19
Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?
Nicola Normanno, Alessandro Morabito, Anna Maria Rachiglio, et al.
Nature Reviews Clinical Oncology (2025)
Closed Access | Times Cited: 2
Management of locally advanced non‐small cell lung cancer: State of the art and future directions
Da Miao, Jing Zhao, Ying Han, et al.
Cancer Communications (2023) Vol. 44, Iss. 1, pp. 23-46
Open Access | Times Cited: 41
Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2–IA3 EGFR-Mutated NSCLC: ADAURA2
Yasuhiro Tsutani, Jonathan W. Goldman, Sanja Đačić, et al.
Clinical Lung Cancer (2023) Vol. 24, Iss. 4, pp. 376-380
Open Access | Times Cited: 36
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed
Anushka Walia, Jordan Tuia, Vinay Prasad
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 12, pp. 885-895
Open Access | Times Cited: 28
Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation
John R. Gosney, Luis Paz‐Ares, Pasi A. Jänne, et al.
ESMO Open (2023) Vol. 8, Iss. 4, pp. 101587-101587
Open Access | Times Cited: 26
Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer (BLOSSOM)
Sehhoon Park, Richard Baldry, Hyun Ae Jung, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 23, pp. 2747-2756
Open Access | Times Cited: 14
ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer
Aakash Desai, Tadana A. Vázquez, Keishla M. Arce, et al.
Cancers (2024) Vol. 16, Iss. 5, pp. 940-940
Open Access | Times Cited: 13
Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma
Jiaqi Liang, Guoshu Bi, Qihai Sui, et al.
Cell Reports (2024) Vol. 43, Iss. 2, pp. 113771-113771
Open Access | Times Cited: 12
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Fei Zhou, Haoyue Guo, Yang Xia, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 10
The hype around ctDNA guiding an informed perioperative therapeutic strategy in early-stage non-small cell lung cancer
Gaia Passarella, Stefania Canova, Maria Ida Abbate, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Long-term outcomes of neoadjuvant gefitinib in resectable stage II-IIIA non-small cell lung cancer: A phase II, prospective cohort study
Zhanming Ma, Fangqiu Fu, Yang Zhang, et al.
Lung Cancer (2025) Vol. 201, pp. 108457-108457
Closed Access | Times Cited: 1
Evolving Paradigms in Lung Cancer: Latest Trends in Diagnosis, Management, and Radiopharmaceuticals
Busra Cangut, Rahman Akinlusi, Ava Mohseny, et al.
Seminars in Nuclear Medicine (2025)
Closed Access | Times Cited: 1
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer
Roy S. Herbst, Thomas John, Christian Grohé, et al.
Nature Medicine (2025)
Open Access | Times Cited: 1
Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges
Jordi Remón, Stephanie P.L. Saw, Francesco Cortiula, et al.
Journal of Thoracic Oncology (2023) Vol. 19, Iss. 2, pp. 199-215
Open Access | Times Cited: 18
Receptor tyrosine kinases: biological functions and anticancer targeted therapy
Nan Zhang, Yongsheng Li
MedComm (2023) Vol. 4, Iss. 6
Open Access | Times Cited: 18
Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis
Zhuchen Yu, Fei Xu, Juntao Zou
European Journal of Clinical Pharmacology (2024) Vol. 80, Iss. 4, pp. 505-517
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top